Efficacy and Safety of Ombitasvir/ Paritaprevir / Ritonavir Plus Ribavirin in Management HCV Genotype 4 and End-stage Kidney Disease With or Without Hemodialysis (An Open Label- Multicenter Prospective Study)
Phase of Trial: Phase IV
Latest Information Update: 18 Jan 2019
Price : $35 *
At a glance
- Drugs Ombitasvir/paritaprevir/ritonavir (Primary)
- Indications Hepatitis C
- Focus Therapeutic Use
- 10 Jan 2019 Status changed from recruiting to completed.
- 11 May 2018 Status changed from not yet recruiting to recruiting.
- 19 Apr 2018 New trial record